Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2/3, Open-Label, Dose Escalation, Dose Expansion and Randomized, Controlled Study to Evaluate the Safety and Efficacy of ATSN-201 Gene Therapy in Subjects With RS1-Associated X-linked Retinoschisis (LIGHTHOUSE)

NCT05878860 is registered in ClinicalTrials.gov with Atsena Therapeutics Inc. as lead sponsor.

NCT NCT05878860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05878860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2/3, Open-Label, Dose Escalation, Dose Expansion and Randomized, Controlled Study to Evaluate the Safety and Efficacy of ATSN-201 Gene Therapy in Subjects With RS1-Associated X-linked Retinoschisis (LIGHTHOUSE)
Lead sponsor
Atsena Therapeutics Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
August 22, 2023
Completion date
April 30, 2033
Enrollment
97 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

x-linked retinoschisis